There is no commercial support for this activity.

About the speaker

Petros Levounis, MD, MA, serves as professor and chair of the Department of Psychiatry and associate dean for professional development at Rutgers New Jersey Medical School. He is also the chief of service at University Hospital in Newark, New Jersey, and president-elect of the American Psychiatric Association. Dr. Levounis came to Rutgers from Columbia University where he served as director of the Addiction Institute of New York from 2002 to 2013.

Dr. Levounis is a Phi Beta Kappa graduate of Stanford University where he studied chemistry and biophysics before receiving his medical education at Stanford University School of Medicine and the Medical College of Pennsylvania. During medical school, he researched the effects of social class on patient-physician relationships in Oxford, England, and received an MA degree in sociology from Stanford. In 1994, he moved to New York City to train in psychiatry at the New York State Psychiatric Institute of Columbia University. He graduated from Columbia earning the National Institute of Mental Health Outstanding Resident Award and went on to complete his fellowship in addiction psychiatry at New York University.

Dr. Levounis has served on the boards of the American Society of Addiction Medicine (ASAM) and the American Board of Addiction Medicine, and from 2005 to 2009 chaired the national Committee on Addiction Treatment of the American Psychiatric Association (APA). Dr. Levounis is a Betty Ford Scholar, a recipient of the Association of Gay and Lesbian Psychiatrists’ Distinguished Service Award and the ASAM Educator of the Year Award, and a distinguished fellow of the APA and ASAM. In 2017, he was elected as an honorary member of the World Psychiatric Association.

Disclosure Statements

Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers, speakers and persons in control of content have been asked to disclose any relationship he /she has with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt Health System, and if there will be discussion of any products, services or off-label uses of product(s) during this presentation.

Petros Levounis, MD, MA., reports that he has no relationships with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 24 months. He will discuss off-label naltrexone and antidepressants for technological addictions.

Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months: Todd Peters, MD, Deepak Prabhakar, MD, Elizabeth Ryznar, MD, MSc., Louis Marino, MD, Ehsan Syed, MD, Devi Bhuyan, PhD, Faith Dickerson, PhD, Carrie Etheridge, LCSW-C, Tom Flis, LCPC, Laura Webb, RN-BC, MSN,  Stacey Garnett, RN, MSN, Octavia Coit, MN, Heather Billings, RN, Lisa Illum, MLIS, MEd, and Jennifer Tornabene.